Amyloid-β and synaptic activity in mice and men

NeuroReport

Volumn 18, Issue 12, 2007, Pages 1205-1206

  Ihara, Masafumi ^a   Kalaria, Raj N ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ALZHEIMER DISEASE; ANGIOGENESIS; BRAIN CORTEX; CHOLESTEROL METABOLISM; EDITORIAL; HUMAN; IMMUNOTHERAPY; LIPID TRANSPORT; LONG TERM POTENTIATION; MENINGOENCEPHALITIS; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SENILE PLAQUE; SYNAPTIC MEMBRANE; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; LONG-TERM POTENTIATION; MICE; PEPTIDE FRAGMENTS; SENILE PLAQUES; SYNAPTIC TRANSMISSION;

EID: 34447507885     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e32823ed031     Document Type: Editorial

References (13)

1. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8:101-112.
2. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001; 56:127-129.
3. Matsuyama S, Teraoka R, Mori H, Tomiyama T. Inverse correlation between APP and synaptic plasticity in transgenic mice. NeuroReport 2007; 18:1083-1087.
4. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8:1051-1058.
5. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, et al. APP processing and synaptic function. Neuron 2003; 37:925-937.
6. Valla J, Schneider LE, Gonzalez-Lima F, Reiman EM. Nonprogressive transgene-related callosal and hippocampal changes in PDAPP mice. NeuroReport 2006; 17:829-832.
7. Schenk D, Hagen M, Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 2004; 16:599-606.
8. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 2006; 169:1048-1063.
9. Kalaria RN. Cerebral vessels in ageing and Alzheimer's disease. Pharm Therap 1996; 72:193-214.
10. Ambree O, Leimer U, Herring A, Gortz N, Sachser N, Heneka MT, et al. Reduction of amyloid angiopathy and Abeta plaque burden after enriched housing in TgCRND8 mice: involvement of multiple pathways. Am J Pathol 2006; 169:544-552.
11. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 2005; 120:701-713.
12. Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci 2007; 34:621-628.
13. Roman GC, Kalaria RN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 2006; 27: 1769-1785.